Actively Recruiting
Evaluation of TYRA-300 Dose and Safety in Children Aged 3 to 10 With Achondroplasia and Open Growth Plates
Led by Tyra Biosciences, Inc · Updated on 2026-10-01
92
Participants Needed
25
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating TYRA-300, a selective FGFR-3 tyrosine kinase inhibitor, in children aged 3 to 10 years with achondroplasia who have open growth plates. This Phase 2 multicenter open-label study aims to assess the safety, tolerability, and identify potentially effective doses of TYRA-300. The study includes three groups of children the Sentinel Safety Cohort, Cohort 1, and Cohort 2, differentiating participants by prior growth therapy exposure and age. Participants receive TYRA-300 as sprinkle capsules or mini-tablets, with doses calculated based on body weight and adjusted every 3 months. The study uses a dose-escalation design with five dose levels ranging from 0.125 mgkg to 0.625 mgkg. Treatment is administered orally, and dose increases follow protocol criteria. The study monitors participants over up to 12 months, focusing on safety and growth outcomes. Throughout the study, participants undergo assessments including adverse event monitoring, growth velocity measurements, and pharmacokinetic testing. Evaluations include height and limb measurements, arm span ratios, and elbow extension. Safety is assessed using standardized criteria for treatment-related adverse events. Weight adjustments and clinical visits occur regularly to monitor progress. The total study duration extends up to 12 months, with detailed follow-up of growth and safety parameters.
CONDITIONS
Brief Title
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Research Team
L
Lara Balick
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here